Lilly Playing Catch Up In Oncology
The big pharma is chasing the competition in multiple areas of oncology, bringing forward offerings in CDK 4/6, as well as PD-L1.
The big pharma is chasing the competition in multiple areas of oncology, bringing forward offerings in CDK 4/6, as well as PD-L1.